vs
Lakeside Holding Ltd（LSH）与TriSalus Life Sciences, Inc.（TLSI）财务数据对比。点击上方公司名可切换其他公司
TriSalus Life Sciences, Inc.的季度营收约是Lakeside Holding Ltd的1.9倍（$13.2M vs $7.0M），Lakeside Holding Ltd净利率更高（-22.6% vs -73.9%，领先51.3%），Lakeside Holding Ltd同比增速更快（95.0% vs 59.8%）
莱克赛德出版社是位于美国芝加哥的出版品牌，由RR唐纳利公司运营。该社除了出版高品质书籍外，还承印邮购目录、电话号码簿、百科全书与广告宣传品，最为人熟知的是为芝加哥卡克斯顿俱乐部出版的高端版本，以及经典重印丛书《莱克赛德经典》。
TriSalus生命科学公司是一家临床阶段生物技术企业，专注于免疫肿瘤学与介入肿瘤学领域，研发专有的靶向给药技术，用于提升肝脏、胰腺等难治性实体瘤患者的治疗效果，主要在北美市场开展临床合作及业务运营。
LSH vs TLSI — 直观对比
营收规模更大
TLSI
是对方的1.9倍
$7.0M
营收增速更快
LSH
高出35.2%
59.8%
净利率更高
LSH
高出51.3%
-73.9%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $7.0M | $13.2M |
| 净利润 | $-1.6M | $-9.8M |
| 毛利率 | 27.2% | 86.7% |
| 营业利润率 | -21.3% | -24.8% |
| 净利率 | -22.6% | -73.9% |
| 营收同比 | 95.0% | 59.8% |
| 净利润同比 | 18.7% | 3.5% |
| 每股收益（稀释后） | $-0.08 | $-0.22 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收LSHTLSI
| Q4 25 | $7.0M | $13.2M | ||
| Q3 25 | $6.1M | $11.6M | ||
| Q2 25 | $6.3M | $11.2M | ||
| Q1 25 | $3.8M | $9.2M | ||
| Q4 24 | $3.6M | $8.3M | ||
| Q3 24 | $4.1M | $7.3M | ||
| Q2 24 | — | $7.4M | ||
| Q1 24 | — | $6.5M |
净利润LSHTLSI
| Q4 25 | $-1.6M | $-9.8M | ||
| Q3 25 | $-1.4M | $-10.8M | ||
| Q2 25 | $-893.1K | $-8.3M | ||
| Q1 25 | $-1.1M | $-10.4M | ||
| Q4 24 | $-1.9M | $-10.1M | ||
| Q3 24 | $-1.3M | $-2.4M | ||
| Q2 24 | — | $-4.3M | ||
| Q1 24 | — | $-13.2M |
毛利率LSHTLSI
| Q4 25 | 27.2% | 86.7% | ||
| Q3 25 | 18.2% | 83.5% | ||
| Q2 25 | 26.7% | 83.9% | ||
| Q1 25 | 18.8% | 83.7% | ||
| Q4 24 | -1.2% | 85.3% | ||
| Q3 24 | 12.8% | 86.3% | ||
| Q2 24 | — | 87.6% | ||
| Q1 24 | — | 85.0% |
营业利润率LSHTLSI
| Q4 25 | -21.3% | -24.8% | ||
| Q3 25 | -20.8% | -77.9% | ||
| Q2 25 | -8.9% | -65.4% | ||
| Q1 25 | -28.2% | -79.9% | ||
| Q4 24 | -55.6% | -91.8% | ||
| Q3 24 | -32.5% | -118.9% | ||
| Q2 24 | — | -111.0% | ||
| Q1 24 | — | -180.8% |
净利率LSHTLSI
| Q4 25 | -22.6% | -73.9% | ||
| Q3 25 | -22.2% | -93.5% | ||
| Q2 25 | -14.2% | -73.9% | ||
| Q1 25 | -28.2% | -113.2% | ||
| Q4 24 | -54.1% | -122.4% | ||
| Q3 24 | -32.7% | -32.6% | ||
| Q2 24 | — | -58.8% | ||
| Q1 24 | — | -204.5% |
每股收益（稀释后）LSHTLSI
| Q4 25 | $-0.08 | $-0.22 | ||
| Q3 25 | $-0.09 | $-0.96 | ||
| Q2 25 | $-0.11 | $-0.27 | ||
| Q1 25 | $-0.14 | $-0.39 | ||
| Q4 24 | $-0.26 | $-0.38 | ||
| Q3 24 | $-0.18 | $-0.12 | ||
| Q2 24 | — | $-0.21 | ||
| Q1 24 | — | $-0.60 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.6M | $20.4M |
| 总债务越低越好 | $2.4M | — |
| 股东权益账面价值 | $12.2M | $-33.9M |
| 总资产 | $24.3M | $35.3M |
| 负债/权益比越低杠杆越低 | 0.20× | — |
8季度趋势，按日历期对齐
现金及短期投资LSHTLSI
| Q4 25 | $1.6M | $20.4M | ||
| Q3 25 | $4.5M | $22.7M | ||
| Q2 25 | $5.0M | $26.5M | ||
| Q1 25 | $1.5M | $13.0M | ||
| Q4 24 | $1.1M | $8.5M | ||
| Q3 24 | $2.7M | $11.3M | ||
| Q2 24 | — | $16.5M | ||
| Q1 24 | — | $4.0M |
总债务LSHTLSI
| Q4 25 | $2.4M | — | ||
| Q3 25 | $2.4M | — | ||
| Q2 25 | $1.4M | — | ||
| Q1 25 | $774.2K | — | ||
| Q4 24 | $784.8K | — | ||
| Q3 24 | $589.9K | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益LSHTLSI
| Q4 25 | $12.2M | $-33.9M | ||
| Q3 25 | $7.0M | $-26.7M | ||
| Q2 25 | $2.8M | $-19.4M | ||
| Q1 25 | $749.8K | $-34.4M | ||
| Q4 24 | $1.6M | $-25.9M | ||
| Q3 24 | $3.6M | $-20.4M | ||
| Q2 24 | — | $-25.3M | ||
| Q1 24 | — | $-36.0M |
总资产LSHTLSI
| Q4 25 | $24.3M | $35.3M | ||
| Q3 25 | $18.6M | $36.5M | ||
| Q2 25 | $14.4M | $41.3M | ||
| Q1 25 | $9.9M | $28.6M | ||
| Q4 24 | $9.8M | $24.0M | ||
| Q3 24 | $10.8M | $27.5M | ||
| Q2 24 | — | $32.4M | ||
| Q1 24 | — | $17.9M |
负债/权益比LSHTLSI
| Q4 25 | 0.20× | — | ||
| Q3 25 | 0.35× | — | ||
| Q2 25 | 0.48× | — | ||
| Q1 25 | 1.03× | — | ||
| Q4 24 | 0.48× | — | ||
| Q3 24 | 0.16× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-453.5K | $-2.5M |
| 自由现金流经营现金流 - 资本支出 | — | $-2.5M |
| 自由现金流率自由现金流/营收 | — | -19.1% |
| 资本支出强度资本支出/营收 | — | 0.3% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-19.1M |
8季度趋势，按日历期对齐
经营现金流LSHTLSI
| Q4 25 | $-453.5K | $-2.5M | ||
| Q3 25 | $-4.0M | $-3.7M | ||
| Q2 25 | $-483.7K | $-7.3M | ||
| Q1 25 | $-238.3K | $-4.5M | ||
| Q4 24 | $-530.2K | $-5.7M | ||
| Q3 24 | $-1.4M | $-10.8M | ||
| Q2 24 | — | $-13.4M | ||
| Q1 24 | — | $-10.9M |
自由现金流LSHTLSI
| Q4 25 | — | $-2.5M | ||
| Q3 25 | — | $-3.9M | ||
| Q2 25 | $-497.4K | $-7.4M | ||
| Q1 25 | — | $-5.3M | ||
| Q4 24 | $-560.5K | $-5.8M | ||
| Q3 24 | $-1.4M | $-11.0M | ||
| Q2 24 | — | $-13.5M | ||
| Q1 24 | — | $-10.9M |
自由现金流率LSHTLSI
| Q4 25 | — | -19.1% | ||
| Q3 25 | — | -33.9% | ||
| Q2 25 | -7.9% | -66.1% | ||
| Q1 25 | — | -57.3% | ||
| Q4 24 | -15.6% | -69.7% | ||
| Q3 24 | -34.5% | -149.9% | ||
| Q2 24 | — | -183.1% | ||
| Q1 24 | — | -169.3% |
资本支出强度LSHTLSI
| Q4 25 | — | 0.3% | ||
| Q3 25 | — | 1.9% | ||
| Q2 25 | 0.2% | 0.8% | ||
| Q1 25 | 0.0% | 8.2% | ||
| Q4 24 | 0.8% | 0.6% | ||
| Q3 24 | 0.1% | 2.3% | ||
| Q2 24 | — | 0.8% | ||
| Q1 24 | — | 1.0% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
LSH
| Transferred Over Time | $4.6M | 65% |
| Distribution Of Pharmaceutical Products | $2.4M | 35% |
TLSI
暂无分部数据
